BEAT News and Press, Heartbeam Inc. From 03/05/24

HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that it will hold a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2023. During the call, slate...

HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, will hold a conference call on Wednesday March 20, 2024 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year end...

2023-12-21 12:18:35 ET Gainers: Infrared Cameras Holdings ( MSAI ) +195% . Mullen Automotive ( MULN ) +112% . Baijiayun Group Ltd ( RTC ) +33% . HeartBeam ( BEAT ) +31% . Triumph Group ( TGI ) +32% . TC BioPharm ( TCBP ) ...

HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced significant developments for the use of artificial intelligence (“AI”) applied to its proprietary vectorelectrocardiography ( ...

Company Appoints Mohammad Shokoohi-Yekta to Lead Program and Industry Pioneer Lance Myers as Advisor HeartBeam, Inc . (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced significant development...

HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for artificial intelligence (“AI”), is reporting...

2023-11-14 19:10:26 ET HeartBeam, Inc. (BEAT) Q3 2023 Earnings Conference Call November 14, 2023 04:30 PM ET Company Participants Branislav Vajdic - Chief Executive Officer & Founder Rob Eno - President Rick Brounstein - Chief Financial Officer Conferen...

2023-11-14 16:03:35 ET HeartBeam press release ( NASDAQ: BEAT ): Q3 GAAP EPS of -$0.13 in-line. Cash and cash equivalents totaled approximately $19.2 million as of September 30, 2023. For further details see: HeartBeam GAAP EPS of -$0.13 in-line

Strengthens Leadership with Appointments to Executive Team and Boards Publishes Landmark Peer-Reviewed Article, Validating Technology Ongoing Clinical and Regulatory Progress for the HeartBeam AIMIGo ™ VECG Device Management to Host Webcast and Conference Call T...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...